Table 1.
Baseline characteristics of the Taiwanese subgroup and the overall RELAY ITT population
| Taiwanese subgroup | Overall RELAY ITT populationa | |||
|---|---|---|---|---|
| RAM+ERL (n = 26) | PBO+ERL (n = 30) | RAM+ERL (n = 224) | PBO+ERL (n = 225) | |
| Sex, n (%) | ||||
| Male | 11 (42) | 10 (33) | 83 (37) | 83 (37) |
| Female | 15 (58) | 20 (67) | 141 (63) | 142 (63) |
| Age, median (IQR), years | 55 (46–62) | 61 (54–66) | 65 (57–71) | 64 (56–70) |
| Ever smokers, n (%) | 7 (27) | 8 (27) | 64 (29) | 73 (32) |
| ECOG PS 0, n (%) | 19 (73) | 20 (67) | 116 (52) | 119 (53) |
| EGFR mutation, n (%) | ||||
| Exon 19 deletion | 12 (46) | 12 (40) | 123 (55) | 120 (53) |
| Exon 21 (L858R) substitution | 13 (50) | 18 (60) | 99 (44) | 105 (47) |
| Otherb | 1 (4) | 0 | 1 (<1) | 0 |
aData published in Nakagawa et al. 2019 [20].
bOne patient enrolled with an exon 21 mutation other than L858R and was reported as an important protocol deviation. The patient continued to receive study treatment due to continued treatment benefit and was subsequently discontinued from study prior to cycle 30
ECOG European Cooperative Oncology Group, EGFR epidermal growth factor receptor, ERL erlotinib, IQR interquartile range, ITT intention to treat, PBO placebo, RAM ramucirumab